sup 18^F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer
Although endocrine therapy is an effective method to treat estrogen receptor (ER)-positive breast cancer, approximately 30%-40% of all hormone receptor-positive tumors display de novo resistance. The aim of our current study was to analyze whether ...F-labeled fluoromisonidazole (1-(2-nitro-1-imidaz...
Gespeichert in:
Veröffentlicht in: | The Journal of nuclear medicine (1978) 2013-03, Vol.54 (3), p.333 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 3 |
container_start_page | 333 |
container_title | The Journal of nuclear medicine (1978) |
container_volume | 54 |
creator | Cheng, Jingyi Lei, Li Xu, Junyan Sun, Yifei Zhang, Yongping Wang, Xincun Pan, Lingling Shao, Zhimin Zhang, Yingjian Liu, Guangyu |
description | Although endocrine therapy is an effective method to treat estrogen receptor (ER)-positive breast cancer, approximately 30%-40% of all hormone receptor-positive tumors display de novo resistance. The aim of our current study was to analyze whether ...F-labeled fluoromisonidazole (1-(2-nitro-1-imidazolyl)-2-hydroxy-3-fluoropropane [18F-FMISO]) PET/CT could predict primary resistance to hormonal therapy in ER-positive breast cancer. Postmenopausal women who had ER-α-positive breast cancer, stages II-IV, and had never received prior endocrine therapy were prospectively enrolled in this study. Patients underwent both ...F-FDG and ...F-FMISO PET/CT scans before and after treatment. The hottest ...F-FDG standardized uptake value (SUV) in the tumor foci, the SUVs at 2 and 4 h, and the TBR2 h and TBR4 h for the target lesions were calculated (TBR2 h = SUV2 hT/SUV2 hB and TBR4 h = SUV4 hT/SUV4 h... [TBR is the tumor-to-background ratio]). Clinical outcomes of primary endocrine therapy with letrozole were evaluated according to the criteria of the World Health Organization after at least 3 mo of treatment. Immunohistochemistry for markers of proliferation (Ki67) and hypoxia-induced factor 1α was performed on a subset of tumors that had undergone biopsy or surgery. Pearson and Spearman analysis was used to determine the correlation between the parameters of ...F-FDG and ...F-FMISO uptake and clinical or immunohistochemistry outcomes with a 0.01 threshold for statistical significance. A total of 45 lesions (13 primary, 32 metastatic) from 20 patients met the inclusion criteria in this study. Baseline ...F-FDG and ...F-FMISO PET/CT scans were obtained for 33 lesions from 16 patients. The correlation between baseline ...F-FDG uptake and clinical outcome was weak and did not reach statistical significance (r = 0.37, P = 0.031). However, there was a significantly positive correlation between baseline ...F-FMISO uptake (SUV2 hT, TBR2 h, SUV4 hT, and TBR4 h) and clinical outcomes after ≥3 mo of primary endocrine therapy with letrozole (r = 0.77, 0.76, 0.71, and 0.78, respectively; P < 0.0001). The application of a TBR4 h cutoff of ≥1.2 allowed the prediction of 88% of the cases of progressive disease (15/17). Despite poor correlation between ...F-FMISO uptake and hypoxia-induced factor 1α expression, a marginal positive correlation between TBR4 h and Ki67 expression was measured (r = 0.51, P = 0.011) in a subset of malignant lesions acquired by biopsy or surgery. ...F-FMISO |
format | Article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1424396801</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3046999401</sourcerecordid><originalsourceid>FETCH-proquest_journals_14243968013</originalsourceid><addsrcrecordid>eNqNis1KxDAURoMoWH_e4YLrYmInMbrT0uKyDFk7hPaOZsjk1pt0UZ_eEXwAV985nO9MVEo3utbGPJ6LSiqjaq2lvhRXOR-klMZaW4k1LzMo-97XfVyI6RgypTD5b4oIQ-fuW_cMLzBQwVSCj-CIIuyJYWCcwlhC-jhhOHpeoUsTjRwSgvtE9vMKW8whF59GhJDgldHnAu2v84242PuY8fZvr8Vd37n2rZ6ZvhbMZXeghdMp7dTmYdM8GStV87_XDyI0TiE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1424396801</pqid></control><display><type>article</type><title>sup 18^F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Cheng, Jingyi ; Lei, Li ; Xu, Junyan ; Sun, Yifei ; Zhang, Yongping ; Wang, Xincun ; Pan, Lingling ; Shao, Zhimin ; Zhang, Yingjian ; Liu, Guangyu</creator><creatorcontrib>Cheng, Jingyi ; Lei, Li ; Xu, Junyan ; Sun, Yifei ; Zhang, Yongping ; Wang, Xincun ; Pan, Lingling ; Shao, Zhimin ; Zhang, Yingjian ; Liu, Guangyu</creatorcontrib><description>Although endocrine therapy is an effective method to treat estrogen receptor (ER)-positive breast cancer, approximately 30%-40% of all hormone receptor-positive tumors display de novo resistance. The aim of our current study was to analyze whether ...F-labeled fluoromisonidazole (1-(2-nitro-1-imidazolyl)-2-hydroxy-3-fluoropropane [18F-FMISO]) PET/CT could predict primary resistance to hormonal therapy in ER-positive breast cancer. Postmenopausal women who had ER-α-positive breast cancer, stages II-IV, and had never received prior endocrine therapy were prospectively enrolled in this study. Patients underwent both ...F-FDG and ...F-FMISO PET/CT scans before and after treatment. The hottest ...F-FDG standardized uptake value (SUV) in the tumor foci, the SUVs at 2 and 4 h, and the TBR2 h and TBR4 h for the target lesions were calculated (TBR2 h = SUV2 hT/SUV2 hB and TBR4 h = SUV4 hT/SUV4 h... [TBR is the tumor-to-background ratio]). Clinical outcomes of primary endocrine therapy with letrozole were evaluated according to the criteria of the World Health Organization after at least 3 mo of treatment. Immunohistochemistry for markers of proliferation (Ki67) and hypoxia-induced factor 1α was performed on a subset of tumors that had undergone biopsy or surgery. Pearson and Spearman analysis was used to determine the correlation between the parameters of ...F-FDG and ...F-FMISO uptake and clinical or immunohistochemistry outcomes with a 0.01 threshold for statistical significance. A total of 45 lesions (13 primary, 32 metastatic) from 20 patients met the inclusion criteria in this study. Baseline ...F-FDG and ...F-FMISO PET/CT scans were obtained for 33 lesions from 16 patients. The correlation between baseline ...F-FDG uptake and clinical outcome was weak and did not reach statistical significance (r = 0.37, P = 0.031). However, there was a significantly positive correlation between baseline ...F-FMISO uptake (SUV2 hT, TBR2 h, SUV4 hT, and TBR4 h) and clinical outcomes after ≥3 mo of primary endocrine therapy with letrozole (r = 0.77, 0.76, 0.71, and 0.78, respectively; P < 0.0001). The application of a TBR4 h cutoff of ≥1.2 allowed the prediction of 88% of the cases of progressive disease (15/17). Despite poor correlation between ...F-FMISO uptake and hypoxia-induced factor 1α expression, a marginal positive correlation between TBR4 h and Ki67 expression was measured (r = 0.51, P = 0.011) in a subset of malignant lesions acquired by biopsy or surgery. ...F-FMISO PET/CT can be used to predict primary endocrine resistance in ER-positive breast cancer. (ProQuest: ... denotes formulae/symbols omitted.)</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>CODEN: JNMEAQ</identifier><language>eng</language><publisher>New York: Society of Nuclear Medicine</publisher><subject>Breast cancer ; Clinical outcomes ; Drug resistance ; Endocrine therapy ; Immunohistochemistry ; Oncology ; Tomography</subject><ispartof>The Journal of nuclear medicine (1978), 2013-03, Vol.54 (3), p.333</ispartof><rights>Copyright Society of Nuclear Medicine Mar 1, 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Cheng, Jingyi</creatorcontrib><creatorcontrib>Lei, Li</creatorcontrib><creatorcontrib>Xu, Junyan</creatorcontrib><creatorcontrib>Sun, Yifei</creatorcontrib><creatorcontrib>Zhang, Yongping</creatorcontrib><creatorcontrib>Wang, Xincun</creatorcontrib><creatorcontrib>Pan, Lingling</creatorcontrib><creatorcontrib>Shao, Zhimin</creatorcontrib><creatorcontrib>Zhang, Yingjian</creatorcontrib><creatorcontrib>Liu, Guangyu</creatorcontrib><title>sup 18^F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer</title><title>The Journal of nuclear medicine (1978)</title><description>Although endocrine therapy is an effective method to treat estrogen receptor (ER)-positive breast cancer, approximately 30%-40% of all hormone receptor-positive tumors display de novo resistance. The aim of our current study was to analyze whether ...F-labeled fluoromisonidazole (1-(2-nitro-1-imidazolyl)-2-hydroxy-3-fluoropropane [18F-FMISO]) PET/CT could predict primary resistance to hormonal therapy in ER-positive breast cancer. Postmenopausal women who had ER-α-positive breast cancer, stages II-IV, and had never received prior endocrine therapy were prospectively enrolled in this study. Patients underwent both ...F-FDG and ...F-FMISO PET/CT scans before and after treatment. The hottest ...F-FDG standardized uptake value (SUV) in the tumor foci, the SUVs at 2 and 4 h, and the TBR2 h and TBR4 h for the target lesions were calculated (TBR2 h = SUV2 hT/SUV2 hB and TBR4 h = SUV4 hT/SUV4 h... [TBR is the tumor-to-background ratio]). Clinical outcomes of primary endocrine therapy with letrozole were evaluated according to the criteria of the World Health Organization after at least 3 mo of treatment. Immunohistochemistry for markers of proliferation (Ki67) and hypoxia-induced factor 1α was performed on a subset of tumors that had undergone biopsy or surgery. Pearson and Spearman analysis was used to determine the correlation between the parameters of ...F-FDG and ...F-FMISO uptake and clinical or immunohistochemistry outcomes with a 0.01 threshold for statistical significance. A total of 45 lesions (13 primary, 32 metastatic) from 20 patients met the inclusion criteria in this study. Baseline ...F-FDG and ...F-FMISO PET/CT scans were obtained for 33 lesions from 16 patients. The correlation between baseline ...F-FDG uptake and clinical outcome was weak and did not reach statistical significance (r = 0.37, P = 0.031). However, there was a significantly positive correlation between baseline ...F-FMISO uptake (SUV2 hT, TBR2 h, SUV4 hT, and TBR4 h) and clinical outcomes after ≥3 mo of primary endocrine therapy with letrozole (r = 0.77, 0.76, 0.71, and 0.78, respectively; P < 0.0001). The application of a TBR4 h cutoff of ≥1.2 allowed the prediction of 88% of the cases of progressive disease (15/17). Despite poor correlation between ...F-FMISO uptake and hypoxia-induced factor 1α expression, a marginal positive correlation between TBR4 h and Ki67 expression was measured (r = 0.51, P = 0.011) in a subset of malignant lesions acquired by biopsy or surgery. ...F-FMISO PET/CT can be used to predict primary endocrine resistance in ER-positive breast cancer. (ProQuest: ... denotes formulae/symbols omitted.)</description><subject>Breast cancer</subject><subject>Clinical outcomes</subject><subject>Drug resistance</subject><subject>Endocrine therapy</subject><subject>Immunohistochemistry</subject><subject>Oncology</subject><subject>Tomography</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqNis1KxDAURoMoWH_e4YLrYmInMbrT0uKyDFk7hPaOZsjk1pt0UZ_eEXwAV985nO9MVEo3utbGPJ6LSiqjaq2lvhRXOR-klMZaW4k1LzMo-97XfVyI6RgypTD5b4oIQ-fuW_cMLzBQwVSCj-CIIuyJYWCcwlhC-jhhOHpeoUsTjRwSgvtE9vMKW8whF59GhJDgldHnAu2v84242PuY8fZvr8Vd37n2rZ6ZvhbMZXeghdMp7dTmYdM8GStV87_XDyI0TiE</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>Cheng, Jingyi</creator><creator>Lei, Li</creator><creator>Xu, Junyan</creator><creator>Sun, Yifei</creator><creator>Zhang, Yongping</creator><creator>Wang, Xincun</creator><creator>Pan, Lingling</creator><creator>Shao, Zhimin</creator><creator>Zhang, Yingjian</creator><creator>Liu, Guangyu</creator><general>Society of Nuclear Medicine</general><scope>4T-</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>20130301</creationdate><title>sup 18^F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer</title><author>Cheng, Jingyi ; Lei, Li ; Xu, Junyan ; Sun, Yifei ; Zhang, Yongping ; Wang, Xincun ; Pan, Lingling ; Shao, Zhimin ; Zhang, Yingjian ; Liu, Guangyu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_14243968013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Breast cancer</topic><topic>Clinical outcomes</topic><topic>Drug resistance</topic><topic>Endocrine therapy</topic><topic>Immunohistochemistry</topic><topic>Oncology</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheng, Jingyi</creatorcontrib><creatorcontrib>Lei, Li</creatorcontrib><creatorcontrib>Xu, Junyan</creatorcontrib><creatorcontrib>Sun, Yifei</creatorcontrib><creatorcontrib>Zhang, Yongping</creatorcontrib><creatorcontrib>Wang, Xincun</creatorcontrib><creatorcontrib>Pan, Lingling</creatorcontrib><creatorcontrib>Shao, Zhimin</creatorcontrib><creatorcontrib>Zhang, Yingjian</creatorcontrib><creatorcontrib>Liu, Guangyu</creatorcontrib><collection>Docstoc</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, Jingyi</au><au>Lei, Li</au><au>Xu, Junyan</au><au>Sun, Yifei</au><au>Zhang, Yongping</au><au>Wang, Xincun</au><au>Pan, Lingling</au><au>Shao, Zhimin</au><au>Zhang, Yingjian</au><au>Liu, Guangyu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>sup 18^F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><date>2013-03-01</date><risdate>2013</risdate><volume>54</volume><issue>3</issue><spage>333</spage><pages>333-</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><coden>JNMEAQ</coden><abstract>Although endocrine therapy is an effective method to treat estrogen receptor (ER)-positive breast cancer, approximately 30%-40% of all hormone receptor-positive tumors display de novo resistance. The aim of our current study was to analyze whether ...F-labeled fluoromisonidazole (1-(2-nitro-1-imidazolyl)-2-hydroxy-3-fluoropropane [18F-FMISO]) PET/CT could predict primary resistance to hormonal therapy in ER-positive breast cancer. Postmenopausal women who had ER-α-positive breast cancer, stages II-IV, and had never received prior endocrine therapy were prospectively enrolled in this study. Patients underwent both ...F-FDG and ...F-FMISO PET/CT scans before and after treatment. The hottest ...F-FDG standardized uptake value (SUV) in the tumor foci, the SUVs at 2 and 4 h, and the TBR2 h and TBR4 h for the target lesions were calculated (TBR2 h = SUV2 hT/SUV2 hB and TBR4 h = SUV4 hT/SUV4 h... [TBR is the tumor-to-background ratio]). Clinical outcomes of primary endocrine therapy with letrozole were evaluated according to the criteria of the World Health Organization after at least 3 mo of treatment. Immunohistochemistry for markers of proliferation (Ki67) and hypoxia-induced factor 1α was performed on a subset of tumors that had undergone biopsy or surgery. Pearson and Spearman analysis was used to determine the correlation between the parameters of ...F-FDG and ...F-FMISO uptake and clinical or immunohistochemistry outcomes with a 0.01 threshold for statistical significance. A total of 45 lesions (13 primary, 32 metastatic) from 20 patients met the inclusion criteria in this study. Baseline ...F-FDG and ...F-FMISO PET/CT scans were obtained for 33 lesions from 16 patients. The correlation between baseline ...F-FDG uptake and clinical outcome was weak and did not reach statistical significance (r = 0.37, P = 0.031). However, there was a significantly positive correlation between baseline ...F-FMISO uptake (SUV2 hT, TBR2 h, SUV4 hT, and TBR4 h) and clinical outcomes after ≥3 mo of primary endocrine therapy with letrozole (r = 0.77, 0.76, 0.71, and 0.78, respectively; P < 0.0001). The application of a TBR4 h cutoff of ≥1.2 allowed the prediction of 88% of the cases of progressive disease (15/17). Despite poor correlation between ...F-FMISO uptake and hypoxia-induced factor 1α expression, a marginal positive correlation between TBR4 h and Ki67 expression was measured (r = 0.51, P = 0.011) in a subset of malignant lesions acquired by biopsy or surgery. ...F-FMISO PET/CT can be used to predict primary endocrine resistance in ER-positive breast cancer. (ProQuest: ... denotes formulae/symbols omitted.)</abstract><cop>New York</cop><pub>Society of Nuclear Medicine</pub></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0161-5505 |
ispartof | The Journal of nuclear medicine (1978), 2013-03, Vol.54 (3), p.333 |
issn | 0161-5505 1535-5667 |
language | eng |
recordid | cdi_proquest_journals_1424396801 |
source | EZB-FREE-00999 freely available EZB journals |
subjects | Breast cancer Clinical outcomes Drug resistance Endocrine therapy Immunohistochemistry Oncology Tomography |
title | sup 18^F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T10%3A26%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=sup%2018%5EF-Fluoromisonidazole%20PET/CT:%20A%20Potential%20Tool%20for%20Predicting%20Primary%20Endocrine%20Therapy%20Resistance%20in%20Breast%20Cancer&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Cheng,%20Jingyi&rft.date=2013-03-01&rft.volume=54&rft.issue=3&rft.spage=333&rft.pages=333-&rft.issn=0161-5505&rft.eissn=1535-5667&rft.coden=JNMEAQ&rft_id=info:doi/&rft_dat=%3Cproquest%3E3046999401%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1424396801&rft_id=info:pmid/&rfr_iscdi=true |